A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sandra Silberman, MD, PhD
CNS Pharmaceuticals, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hopital Pierre Wertheimer
Lyon, France
- Hopital de la Timone
Marseille, France
- Institut de Recherche En Cancerologie de Montpellier
Montpellier, France
- Hopital Pitie-Salpetriere
Paris, France
- Institut de Cancerologie de L'Ouest
Saint-Herblain, France
- Nstitut Universitaire Du Cancer de Toulouse-
Toulouse, France
- Institut de Cancerologie Gustave-Roussy
Villejuif, France
- Servizio Sanitario Regionale Emilia-Romagna - Azienda Usl Di Bologna - Ospedale Bellaria
Bologna, Italy
- Istituto Clinico Humanitas
Milan, Italy
- Hospital Universitari Germans Trias I Pujol
Badalona, Spain
- Hospital Duran I Reynals
L'Hospitalet de Llobregat, Spain
- Hospital Ramón Y Cajal
Madrid, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital Regional Universitario de Malaga Carlos Haya
Málaga, Spain
- Hospital Universitario Virgen Macarena
Seville, Spain
- University Hospital Zurich
Zurich, Switzerland
- University of Arkansas
Little Rock, Arkansas, United States
- Southern California Permanente Medical Group
Los Angeles, California, United States
- University of California Irvine
Orange, California, United States
- University of Califonia San Diego Moores Cancer Center
San Diego, California, United States
- University of California San Francisco
San Francisco, California, United States
- Saint John'S Cancer Institute at Providence Saint John'S Health Center
Santa Monica, California, United States
- Hca Healthcare Research Institute
Englewood, Colorado, United States
- Baptist Md Anderson Cancer Center
Jacksonville, Florida, United States
- Mayo Clinic Florida
Jacksonville, Florida, United States
- Baptist Miami
Miami, Florida, United States
- Piedmont Healthcare
Atlanta, Georgia, United States
- Rush University Cancer Center
Chicago, Illinois, United States
- University of Kentucky
Lexington, Kentucky, United States
- Tulane Cancer Center Clinic
New Orleans, Louisiana, United States
- Tufts Medical Center
Boston, Massachusetts, United States
- Umass (acc) - Hollings Cancer Center (hcc)
Worcester, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Hackensack Meridian Health
Hackensack, New Jersey, United States
- Rutgers University
Piscataway, New Jersey, United States
- Atlantic Healthcare
Summit, New Jersey, United States
- Roswell Park Cancer Center
Buffalo, New York, United States
- Duke University School of Medicine
Durham, North Carolina, United States
- Ohio State University
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 May 2021
- Primary completion
- 27 Apr 2026
- Completion
- 15 Jul 2026
- Last update posted
- 15 Apr 2026
- Registered enrollment
- 252
- Registry id
- NCT04762069
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.